| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.04. | Servier completes the acquisition of Day One Biopharmaceuticals | 1.112 | PR Newswire | Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S. in pediatric low-grade glioma. Transaction also includes a strong oncology pipeline of... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 13.03. | Weekly Buzz: Bristol Myers Squibb Wins FDA Nod; EU Okays Johnson & Johnson's AKEEGA; Ipsen Withdraws Tazverik, Day One Biopharmaceuticals Acquired | 4.064 | AFX News | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas... ► Artikel lesen | |
| 06.03. | Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio | 1.367 | PR Newswire | Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs. Transaction represents... ► Artikel lesen | |
| 06.03. | Day One Biopharmaceuticals, Inc.: Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio | 1.304 | GlobeNewswire (Europe) | Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs Transaction represents total... ► Artikel lesen | |
| 24.02. | Day One Biopharmaceuticals, Inc.: Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance | 702 | GlobeNewswire (Europe) | OJEMDA 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline... ► Artikel lesen | |
| 11.01. | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | 717 | GlobeNewswire (Europe) | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen | |
| 06.01. | Day One Biopharmaceuticals, Inc.: Day One Completes Acquisition of Mersana Therapeutics | 1.118 | GlobeNewswire (Europe) | BRISBANE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) ("Day One"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,15 | 0,00 % | BioNTech-Aktie: Totes Kapital? | Die Aktie von BioNTech bleibt trotz des rückläufigen Impfstoffgeschäfts ein spannender Titel am Aktienmarkt. Anleger richten ihren Blick zunehmend auf die milliardenschwere Forschungspipeline im Bereich... ► Artikel lesen | |
| AMGEN | 415,95 | -0,04 % | Amgen Announces Positive Phase 3 Results For Dazodalibep In Sjögren's Disease | Only Global Phase 3 Trial to Show Clinically Meaningful Improvements in Systemic Disease Activity and Patient-Reported Symptoms of Sjögren's Disease THOUSAND OAKS, Calif., Nov. 11, 2026 /PRNewswire/... ► Artikel lesen | |
| NOVAVAX | 7,200 | -0,41 % | Novavax hebt Prognose an: Worauf es jetzt ankommt | ||
| BIOGEN | 226,05 | -0,83 % | Eisai, Biogen Report Five-Year Leqembi Data Showing Sustained Alzheimer's Benefit | WESTON (dpa-AFX) - Eisai Co., Ltd. (4523.T) and Biogen Inc. (BIIB) presented long-term data from the Phase 3 Clarity AD trial showing that continuous treatment with LEQEMBI (lecanemab-irmb)... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 36,550 | +0,23 % | CRISPR Therapeutics Highlights Substantial Lipid Reductions with Investigational Gene Editing Therapy | ||
| VIKING THERAPEUTICS | 24,600 | +0,61 % | Viking Therapeutics gains amid report of renewed takeover interest | ||
| INTELLIA THERAPEUTICS | 8,920 | +0,45 % | Intellia auf der Jefferies Global Healthcare Conference: Marktstart und Pipeline im Fokus | ||
| TEMPUS AI | 57,74 | +0,23 % | Cathie Wood's weekly recap: boosts Nvidia, CoreWeave, Archer Aviation; pares Tempus AI, Palantir | ||
| BIOCRYST PHARMACEUTICALS | 6,796 | -0,47 % | BioCryst presents real-world data on ORLADEYO at ACAAI meeting | ||
| BIOMARIN PHARMACEUTICAL | 52,96 | -0,38 % | 50 Prozent der neuen US-Arzneien waren Orphan Drugs: Warum BioMarin, Vertex und NurExone kleine Märkte anders entwickeln | ||
| EXELIXIS | 62,01 | -0,35 % | Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change Everything | ||
| SAREPTA THERAPEUTICS | 13,380 | -0,30 % | Sarepta Therapeutics auf Guggenheim-Konferenz: Starker Cashflow finanziert breite Entwicklungspipeline | ||
| CARDIOL THERAPEUTICS | 0,883 | -0,56 % | Cardiol Therapeutics GAAP EPS of -C$0.11 misses by C$0.03 | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,653 | -0,33 % | Pacific BioSciences of California (NDQ:PACB): After a Horror 2 Years, Is This Company About To Reach Its Inflection Point | ||
| VAXART | 0,600 | 0,00 % | Vaxart, Inc.: Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology | European Patent Office granted Vaxart a new patent, extending intellectual property protection for Vaxart's Norovirus vaccine program through at least 2036 across key European marketsKEY HIGHLIGHTS:•... ► Artikel lesen |